Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 6/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 4/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | MARK3 | P27448 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.36 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17749198 | 0.94 | ADK (0.42) | ADKSLC29A1ACACBDYRK3ROCK2 | |
| SCHEMBL17818406 | 0.93 | ADK (0.41) | ADKSLC29A1ACACBDYRK3ROCK2 | |
| SCHEMBL20351626 | 0.91 | ADK (0.42) | ADKSLC29A1ACACBDYRK3ROCK2 | |
| SCHEMBL20351559 | 0.90 | ADK (0.40) | ADKSLC29A1ACACBDYRK3ROCK2 | |
| SCHEMBL398112 | 0.82 | DYRK3 (0.54) | ADKACACBDYRK3ROCK2PRKD3 | |
| SCHEMBL19264267 | 0.82 | ACACB (0.44) | ADKACACBYTHDC1SRCABL1 | |
| SCHEMBL29503417 | 0.78 | ADK (0.46) | ADKSLC29A1DYRK3ROCK2PRKD3 | |
| SCHEMBL16236999 | 0.78 | ADK (0.46) | ADKSLC29A1DYRK3ROCK2PRKD3 | |
| SCHEMBL16236821 | 0.77 | DYRK3 (0.52) | ADKACACBDYRK3ROCK2PRKD3 | |
| SCHEMBL16236456 | 0.77 | ADK (0.43) | ADKSLC29A1DYRK3ROCK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| CN-111689991-B | Substituted heteroaryl compounds, compositions and uses thereof | 习峰 | 2023-06-09 | — | — | CN | disclosed |
| WO-2020182188-A1 | SUBSTITUTED HETEROARYL COMPOUND, COMPOSITION OF SAME, AND USES THEREOF | 习峰 | 2020-09-17 | — | — | WO | disclosed |
| CN-107108631-B | 6-amino-7-bicyclic-7-deaza-purine derivatives as protein kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-03-05 | — | — | US | disclosed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| CN-1960993-A | 6, 6-bicyclic substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC (US) | 2007-05-09 | — | — | CN | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | ADK 790/4885SLC29A1 3579/4885ACACB 3576/4885 |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | ADK 790/4885SLC29A1 3579/4885ACACB 3576/4885 |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | ADK 961/4885SLC29A1 4812/4885ACACB 1956/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | ADK 961/4885SLC29A1 4812/4885ACACB 1956/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | ADK 961/4885SLC29A1 4812/4885ACACB 1956/4885 |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | DCK, RET, PRKCA | ADK 4/4885SLC29A1 596/4885ACACB 3387/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | ADK 790/4885SLC29A1 3579/4885ACACB 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.